Enzo Biochem Inc. Announces Issuance of United States Patent for Treatment of Liver Cancer Using Ozanimod
May 10 2019 - 10:48AM
Business Wire
Enzo Biochem, Inc. (NYSE:ENZ) today announced that on May 7,
2019 it was issued U.S. Patent No. 10,278,960 entitled “Sphingosine
Pathway Modulating Compounds for the Treatment of Cancers” that is
directed to methods for treating hepatocellular carcinoma (HCC),
the most common human liver cancer, using the compound
Ozanimod.
Ozanimod is a product of Celgene Corporation (NASDAQ:CELG) that
is in late-stage clinical development for the treatment of
relapsing multiple sclerosis and inflammatory bowel disease. It
targets a different part of the same cell signaling pathway, the
“sphingosine pathway,” also targeted by Enzo’s proprietary
sphingosine kinase inhibitor, SK1-I, which Enzo is currently
developing for the treatment of HCC. The sphingosine pathway is a
key cellular signaling pathway implicated in various cancers and
functions of the immune system. Enzo has already obtained a number
of U.S. and foreign patents covering SK1-I and its use in the
treatment of cancers.
Elazar Rabbani, CEO of Enzo stated, “Our findings with Ozanimod
provide further validation for targeting the sphingosine pathway in
hepatocellular carcinoma and complement our current program to
develop Enzo’s proprietary sphingosine kinase inhibitor, SK1-I, for
the treatment of HCC. Animal xenotransplantation studies examining
the efficacy of each of SK1-I and Ozanimod against tumors derived
from human liver cancer cells are currently in progress.”
HCC represents more than 90% of primary human liver cancers and
a significant unmet medical need in the United States and
globally.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products, systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
Except for historical information, the matters discussed in this
news release may be considered "forward-looking" statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements include declarations regarding the intent,
belief or current expectations of the Company and its management,
including those related to cash flow, gross margins, revenues, and
expenses which are dependent on a number of factors outside of the
control of the Company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other
expenses, government regulations, litigation, and general business
conditions. See Risk Factors in the Company’s Form 10-K for the
fiscal year ended July 31, 2018. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that
could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of
developments occurring after the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190510005335/en/
For: Enzo Biochem, Inc.Steve Anreder,
212-532-3232steven.anreder@anreder.com
or
Michael Wachs, CEOcast, Inc., 212-732-4300mwachs@ceocast.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024